The Fundamentals of Alpha Decay: A Primer on Nuclear Medicine

Alpha decay is a specific type of radioactive decay in which an unstable atomic nucleus ejects an alpha particle—two protons and two neutrons bound together, identical to the nucleus of a helium-4 atom. This process transforms the original element (parent nuclide) into a new element (daughter nuclide) with an atomic number reduced by two and a mass number reduced by four. The energy released, known as the Q-value, is partitioned between the alpha particle and the recoiling daughter nucleus. For medical applications, the key is that alpha particles possess very high linear energy transfer (LET)—typically around 80–100 keV/µm—meaning they deposit intense energy over extremely short distances (40–100 micrometers in tissue). This property makes alpha emitters uniquely suited for eradicating individual cancer cells while sparing surrounding healthy tissues, a principle exploited in targeted alpha therapy (TAT).

While the concept of using radioactive isotopes for cancer therapy dates back to the early 20th century with radium-226, the modern era of alpha therapy began with the development of short-lived, chemically stable alpha emitters that can be conjugated to targeting vectors such as antibodies, peptides, or small molecules. Understanding the underlying nuclear physics—including half-lives, decay chains, and daughter product toxicity—is essential for designing effective and safe radiopharmaceuticals. The field has grown rapidly, with the U.S. Food and Drug Administration (FDA) approving the first alpha-emitting radiopharmaceutical, radium-223 dichloride (Xofigo), in 2013 for metastatic castration-resistant prostate cancer, and a growing pipeline of investigational agents now entering late-stage clinical trials.

Key Alpha-Emitting Isotopes in Clinical Development

Not all alpha emitters are suitable for cancer therapy. Ideal isotopes have half-lives long enough to allow pharmaceutical preparation and targeting but short enough to limit prolonged radiation exposure. They should also decay to stable or short-lived daughters with minimal toxicity. Below are the most prominent alpha emitters currently in use or under investigation.

Radium-223

Radium-223 (t½ = 11.4 days) decays via a cascade of four alpha emissions to stable lead-207. It is a bone-seeking calcium analog that naturally accumulates in osteoblastic bone metastases. Radium-223 dichloride (Xofigo) is FDA-approved for the treatment of symptomatic bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) with no known visceral metastases. Clinical trials like the ALSYMPCA phase III study demonstrated a significant improvement in overall survival (median 14.9 vs 11.3 months) compared to placebo, along with a delay in symptomatic skeletal events. Despite its efficacy, radium-223 is not suitable for soft-tissue tumors because it does not specifically target non-osseous lesions.

Actinium-225

Actinium-225 (t½ = 9.92 days) decays through a chain of four alpha-emitting daughters (Francium-221, Astatine-217, Bismuth-213, and ultimately Polonium-213) to stable lead-209. Ac-225 is considered a highly potent theranostic isotope because it can be conjugated to targeting agents via chelators (e.g., DOTA). Conjugates such as 225Ac-PSMA-617 have shown remarkable results in patients with advanced prostate cancer who have failed other therapies, with high rates of PSA response and durable disease control. Similarly, 225Ac-DOTATATE is being explored for neuroendocrine tumors, and 225Ac-lintuzumab for acute myeloid leukemia (AML). However, the short-lived daughters (especially Francium-221 and Astatine-217) can translocate from the original targeting vector, leading to off-target kidney toxicity and requiring strategies to mitigate this redistribution, such as the use of renal protectants or optimized chelation chemistry.

Bismuth-213

Bismuth-213 (t½ = 45.6 minutes) is a daughter of Actinium-225 and can be eluted from an 225Ac/213Bi generator for clinical use. Its very short half-life requires rapid synthesis and injection, but also minimizes patient isolation time. 213Bi has been investigated in several phase I and II trials, particularly for leukemias (e.g., 213Bi-lintuzumab for AML) and for intraperitoneal therapy of ovarian cancer. The short range of alpha particles from Bi-213 (≈ 50–80 µm) makes it suitable for targeting micrometastases and single cells.

Thorium-227 and Lead-212

Thorium-227 (t½ = 18.7 days) is under investigation as a prodrug delivered via chelation to antibodies or peptides. It decays to Radium-223, creating a cascade that amplifies the alpha dose. 227Th-labeled antibodies such as 227Th-trastuzumab have shown preclinical efficacy in HER2-positive cancers. Lead-212 (t½ = 10.6 hours) is a beta-emitting predecessor that decays to the alpha emitter Bismuth-212. A 212Pb/212Bi generator system is being used in ongoing clinical trials for various solid tumors, including glioblastoma, when conjugated to the peptide 212Pb-DOTAM-TATE. The advantage of Pb-212 is its stable coordination chemistry and a half-life that permits centralized production and distribution.

Mechanisms of Action: How Alpha Particles Kill Cancer Cells

The therapeutic efficacy of alpha emitters arises from their physical and biological effects on malignant cells.

Direct DNA Damage

Because the energy deposition of an alpha particle is extremely dense along its track, it produces a high density of ionizations in a small volume. When an alpha particle traverses the nucleus of a cancer cell, it causes complex double-strand breaks (DSBs) that are difficult for the cell to repair. Unlike low-LET radiation (e.g., X-rays or beta particles), which largely induces repairable single-strand breaks, alpha particles cause clustered, irreparable damage, leading to cell death through apoptosis, mitotic catastrophe, or senescence. This mechanism is particularly effective against cancer stem cells and hypoxic cells that are radioresistant to conventional radiation. Studies show that only about 3 to 6 alpha particle hits per cell are required to achieve 90% cellular inactivation, compared to several thousand beta particle hits for similar effect.

Bystander Effects and Abscopal Effects

Alpha particles can also induce biological damage beyond the directly hit cells through the bystander effect, where neighboring non-hit cells receive signals from irradiated cells, leading to increased genomic instability, micronuclei formation, or apoptosis. Additionally, alpha therapy has been shown to trigger an immunogenic cell death (ICD), releasing damage-associated molecular patterns (DAMPs) and tumor-associated antigens. This can prime a systemic immune response—the abscopal effect—where tumor cells distant from the site of radiation are also attacked by the immune system. Combination trials with immune checkpoint inhibitors (e.g., anti-PD-1 antibodies) are under way to amplify this effect, potentially turning “cold” tumors into “hot” ones.

Advantages of Alpha Emitters Over Beta and Auger Emitters

  • Higher Linear Energy Transfer (LET): Alpha particles deposit 100–1000 times more energy per unit path length than beta particles. This translates into a higher relative biological effectiveness (RBE), often in the range of 5–20, meaning alpha therapy can overcome hypoxia-mediated radioresistance and DNA repair mechanisms.
  • Short Range in Tissue: The typical range of alpha particles in tissue is only 40–100 µm (2–10 cell diameters). This spares adjacent healthy tissues, especially critical organs such as the bone marrow and kidneys, when the targeting vector localizes to the tumor.
  • Effective Against Micrometastases: The short range is ideal for eliminating small clusters of cancer cells that are difficult to treat with external beam or beta emitters, which have longer ranges and can cause collateral damage to surrounding stroma.
  • Cytotoxicity Independent of Cell Cycle: Unlike many chemotherapies and low-LET radiations, alpha particles kill cells regardless of their cell cycle phase, making them effective against quiescent cancer stem cells.
  • Reduced Need for Oxygen: The DNA damage from alpha particles is less dependent on oxygen fixation; thus, hypoxic regions of tumors do not become resistant, a common failure mode of conventional radiotherapy.

Current Clinical Applications and Notable Trial Results

Prostate Cancer

The most mature clinical application is 223Ra-dichloride for bone metastases in mCRPC. The ALSYMPCA trial (NCT00699751) enrolled 921 patients and reported an overall survival benefit with a hazard ratio of 0.70. Beyond this, 225Ac-PSMA-617 is now a leading candidate. A prospective phase II study published in the Journal of Nuclear Medicine (Kratochwil et al., 2016) showed that 225Ac-PSMA-617 induced a >50% PSA decline in 63% of patients with end-stage mCRPC, including some who had failed 177Lu-PSMA therapy. The therapy was well tolerated, with xerostomia (dry mouth) due to PSMA expression in salivary glands being the main dose-limiting toxicity, a side effect that is being addressed with gland protection and alternative targeting vectors.

Neuroendocrine Tumors

225Ac-DOTATATE (also known as 225Ac-DOTA-TATE) is being investigated in patients with somatostatin receptor-positive neuroendocrine tumors (NETs). A first-in-human study by Zhang et al. (2019) showed a disease control rate of 92% in a small cohort, with manageable nephrotoxicity when renal protectants were used. The high LET of alpha particles may be especially beneficial for treating bulky, somatostatin-resistant NETs that do not respond to beta-emitter therapy with 177Lu-DOTATATE (Lutathera).

Leukemia and Lymphoma

Targeting the CD33 antigen on myeloid leukemic cells, 225Ac-lintuzumab (HuM195) and 213Bi-lintuzumab have undergone phase I/II trials. In a phase I study of 225Ac-lintuzumab for relapsed/refractory AML, the maximum tolerated dose (MTD) was determined and several patients achieved complete remission (CR) or CR with incomplete count recovery (CRi). The short path length of the alpha particles limits damage to the bone marrow microenvironment compared to beta-emitter antibody conjugates. Alpha therapy for lymphomas, targeting CD20 with 213Bi- or 225Ac-labeled rituximab, has shown impressive preclinical efficacy and early clinical promise.

Production and Supply Chain of Alpha Emitters

One of the major barriers to widespread clinical adoption is the limited availability and high cost of alpha-emitting isotopes.

Radium-223 is produced through neutron irradiation of 226Ra in high-flux nuclear reactors, followed by chemical separation. This process is complex and currently performed only in a few facilities (e.g., Institute for Energy Technology in Norway). Actinium-225 can be produced either by proton irradiation of 232Th in cyclotrons (via spallation) or from the decay of 229Th, which is itself derived from 233U stockpiles. The 229Th/225Ac generator offers a relatively simple source but is limited by the global supply of 229Th. The U.S. Department of Energy and other agencies are investing in large-scale 225Ac production using high-energy proton accelerators. Bismuth-213 is conveniently obtained from a 225Ac/213Bi generator, but has the disadvantage of requiring on-site elution with very short half-life, limiting its use to hospitals with specialized radiopharmacy capabilities. Emerging isotopes like 212Pb and 227Th offer more stable production pathways via radium and thorium targets, respectively, and may become more widely available in the near future.

Challenges and Strategies to Overcome Them

Daughter Redistribution and Toxicity

When alpha emitters decay, the recoil energy (~100 keV) can break the chemical bond between the daughter nuclide and its chelator, freeing the daughter to migrate away from the targeting vector. This “recoil effect” is particularly problematic for Ac-225 because the short-lived daughters (Fr-221, At-217, Bi-213, Po-213) are not retained at the tumor site and can accumulate in the kidneys, bladder, or bone marrow, causing off-target toxicity. To manage this, researchers are developing nanomaterials (e.g., mesoporous silica nanoparticles, liposomes, or dendrimers) that encapsulate the entire decay chain, and thus retain the daughters within the therapeutic agent. Another approach is to use “chelator cages” that rebind the daughter atoms rapidly. Additionally, renal protectants such as lysine or arginine infusion (similar to kidney protection in 177Lu-DOTATATE therapy) are used to reduce tubular resorption and subsequent nephrotoxicity.

Targeted Delivery and Specificity

Alpha therapy demands extremely high selectivity for cancer cells because the high LET will kill any cell it enters. Improving delivery relies on high-affinity targeting vectors: antibodies, antibody fragments (scFv, nanobodies), peptides (e.g., PSMA-617, DOTATATE, bombesin), or small molecules. Conjugation chemistry must be robust, using bifunctional chelators such as DOTA, CHX-A”-DTPA, or HOPO (for Ac-225) that stably bind the alpha emitter without altering the biological activity of the vector. Major efforts are underway to increase tumor-to-background ratios through pretargeting strategies (e.g., using bispecific antibodies or click chemistry) that decouple the injection of the targeting agent from the injection of the radionuclide, allowing time for clearance from normal tissues.

Radiation Protection and Regulatory Hurdles

Handling alpha emitters requires specialized facilities because alpha particles are hazardous if inhaled or ingested (internal contamination). Shielding is less demanding than for gamma emitters—alpha particles can be stopped by a sheet of paper or skin—but the daughter nuclides from Ac-225 and Ra-223 emit beta and gamma photons that require lead shielding. Regulatory requirements for 223Ra, 225Ac, and 213Bi involve complex licensing for transportation, preparation, and administration. The U.S. Nuclear Regulatory Commission (NRC) has specific regulations for alpha emitters, and many hospitals need to adapt their radiation safety programs. The development of automated microfluidic synthesizers and shielded lead “hot cells” is reducing the manual handling burden.

Future Directions and Combination Therapies

Alpha-Emitting Nanoparticles and Polymersomes

Nanotechnology offers a way to deliver multiple alpha emitters per targeting molecule, increasing the local radiation dose and potentially retaining recoiling daughters. For instance, 225Ac-labeled gold nanoparticles coated with targeting peptides have shown enhanced tumor retention and reduced kidney uptake in preclinical models. Polymersonnes loaded with 225Ac are also being tested as injectable depots for local therapy, e.g., after surgical resection of glioblastoma to treat residual cells.

Combination with Immunotherapy

Alpha-induced immunogenic cell death has prompted numerous studies combining TAT with immune checkpoint inhibitors (ICIs). A phase I/II trial combining 225Ac-PSMA-617 with pembrolizumab (anti-PD-1) is recruiting for mCRPC. Preclinical data in mouse models show that alpha therapy can increase infiltration of cytotoxic T cells and upregulate PD-L1 expression on tumor cells, potentially synergizing with ICIs. Other combinations being explored include alpha therapy with CAR-T cells (to prime the tumor microenvironment) and with STING agonists to enhance innate immune activation.

Theranostics: Imaging and Therapy with Alpha Emitters

True theranostics require matched imaging/targeting pairs. For Ac-225, the gamma emissions from its daughters (e.g., 218 keV from Fr-221) allow imaging, albeit with poor resolution. Better results are obtained using “alpha mimic” isotopes: 64Cu (PET) or 44Sc (PET) for Ac-225, and 203Pb (SPECT) for 212Pb therapy. The use of surrogate imaging agents enables dosimetry estimation and patient selection, ensuring that only those with sufficient tumor uptake receive alpha therapy.

Global Access and Cost Reduction

The supply of high-activity 225Ac is currently limited to a few curies per year globally, with costs prohibitive for routine use. New production methods using electron linear accelerators (e-linacs) or high-current cyclotrons are under development. The International Atomic Energy Agency (IAEA) is coordinating efforts to establish regional production centers, especially for 225Ac and 213Bi, to democratize access to alpha therapy.

Conclusion

Alpha decay in isotopes offers a transformative tool in the oncology armamentarium. The exquisite potency and spatial precision of alpha particles enable the eradication of cancer cells, including those resistant to other therapies, while sparing normal tissues. From the established use of radium-223 for bone metastases to the rapid emergence of actinium-225 and bismuth-213 in prostate, neuroendocrine, and hematologic malignancies, the clinical evidence is growing. Yet significant challenges remain: ensuring stable isotope supply, minimizing daughter-related toxicity, optimizing targeted delivery, and managing radiological safety. Through continued investment in production infrastructure, innovative nanomaterials, and combination immunotherapy regimens, targeted alpha therapy has the potential to become a cornerstone of precision oncology in the coming decade.

For further reading, see the recent review in Journal of Nuclear Medicine, the IAEA’s publication on Advances in Alpha Emitter Radionuclide Therapy, and the NIH-funded fact sheet on alpha-emitting radionuclides.